Clinical Study on Flumatinib Mesylate Combined with Chemotherapy Followed by Autologous Hematopoietic Cell Transplantation in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Journal Title: Diseases & Research - Year 2023, Vol 3, Issue 1
Abstract
Objective To investigate the clinical efficacy and safety of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients treated with second-generation tyrosine kinase inhibitor (TKI) flumatinib mesylate combined with chemotherapy followed by autologous hematopoietic stem cell transplantation(auto-HSCT). Methods From September 2020 to March 2022, clinical informations of Ph+ALL patients who received flumatinib mesylate, chemotherapy and auto-HSCT were collected and analyzed. Results Of the 8 patients who were enrolled, a median age was 43 years old. The BCR-ABL transcript type was P190 in patients with the exception of one P210. It was determined that 2 patients suffered from tuberculosis (TB), and 1 patient developed central nervous system leukemia (CNSL). All patients got clinical remissions after the chemotherapy. A total of 4 patients (50%) received auto-HSCT in major molecular response (MMR). However, 1 patient (12.5%) relapsed following auto-HSCT and was switched to dasatinib therapy. Flumatinib was used during the induction and consolidation chemotherapy except the period of HSCT. Myelosuppression and infection were the most common side effects. At a median follow-up of 19.22 months, the 1-year OS rate was 75%. Conclusion Flumatinib combined with chemotherapy followed by auto-HSCT in Ph+ALL achieved a great remission rate and safety.
Authors and Affiliations
Shaojuan Cui, Xiaoyan Tan, Jianchuan Deng, Qing Yang, Jia Yao, Nan Zhang, Yan Shen
Keywords
Related Articles
- EP ID EP740138
- DOI 10.54457/DR.202301002
- Views 79
- Downloads 2
Exploring Oncogenic Factors Influence on Multiple Myeloma Progression and Patient Survival
Backgrounds Multiple myeloma (MM), one of the most prevalent hematological malignancies, is characterized by the proliferation of plasma cells within bone marrow and concurrent development of osteolytic lesions. The pers...
Efficacy of Platelet-Rich Plasma Combined with Wen Shen Formula in the Treatment of Thin Endometrium-Related Infertility
Objective To explore the effectiveness of Platelet-Rich Plasma (PRP) combined with Wen Shen Formula in treating thin endometrium. Methods From January 2019 to January 2023, 90 patients with thin endometrium-related infe...
Role of Various Immune Cells in the Tumor Microenvironment
The tumor microenvironment (TME) has numerous promotive and suppressive effects on tumor growth. The TME harbors adaptive and innate immune cells such as T cells, B cells, natural killer (NK) cells, macrophages, neutroph...
Significance of Liquid Biopsy Containing Circulating Tumor DNA (ctDNA) Analysis for Evaluation and Management of Metastatic Cancer
According to the GLOBOCAN 2020 data from WHO, nearly 10 million deaths took place due to cancer thus, cancer became a leading cause of death all over the world. The most common cancer are breast cancer, lung cancer, colo...
Plasma Exchange to Treat Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome after Anti-CD19 Chimeric Antigen Receptor-T Cell Infusion: A Case Report
Adoptive cell immunotherapy with chimeric antigen receptor-T (CAR-T) cells has shown remarkable clinical out-comes. However, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICA...